Introduction: Renal failure is a disease in which the kidneys present a decrease in glomerular filtration, so they are not able to eliminate water and wastes from the blood correctly. It is classified into two types; acute kidney injury (AKI) and chronic kidney disease in which the latter has generated a greater impact in terms of mortality.
Objective: To relate Cystatin C levels and the severity of renal damage in patients with renal failure.
Methods: A descriptive and observational research was carried out with a non-experimental design and a descriptive and exploratory level of research, to develop this research the PRISMA methodology was used, where the main sources used for its development are detailed.
Results: this research describes the generalities about cystatin C, analytical methods, interferences, stability, and the stages of analysis of this biomarker, the same that was classified into pre-analysis, analysis and post-analysis of the test exposing in each of them the most important points involved.
Conclusions: Cystatin C turns out to be a biomarker with a higher accuracy and sensitivity compared to other tests, in terms of clinical utility this test allows early detection of renal failure, and in patients suffering from this disease helps to determine the stage in which they are in this way allows to obtain a better diagnosis and prognosis regarding this condition.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.